CytoDyn Inc. (OTCQB: CYDY) is a Vancouver, Washington-based biotechnology company engaged in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection.

Monoclonal antibodies – soluble proteins produced by the body in response to infections from bacteria, viruses and other pathogens – have become one of the fastest expanding opportunities in the biotech/pharma sector. CytoDyn’s lead drug candidate is PRO 140, one of the leading monoclonal antibodies under development for HIV infection.

PRO 140 belongs to a new class of HIV/AIDS therapeutics intended to protect healthy cells from viral infection. The candidate has been used in more than 200 HIV-infected patients in placebo-controlled and open label FDA-approved clinical trials; has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects; and is designated a “fast track” product candidate by the FDA.

The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially hardly any side effects or toxicity and less frequent dosing requirements, as compared to daily drug therapies currently in use. CytoDyn has received FDA clearance for and currently has two Phase 3 clinical trials underway. The company’s first Phase 3 trial is a pivotal trial with PRO 140 in combination with current standard-of-care antiretroviral therapy (ART) for highly treatment-experienced patients with HIV. This 25-week trial involves only 30 patients with a primary endpoint of just one week of efficacy and the company expects to report primary endpoint results as early as the first quarter of 2017.

The company’s other Phase 3 trial is with PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV. This multicenter, open-label trial is now enrolling 300 patients prequalified with CCR5-tropic HIV-1 infection who are clinically stable on standard-of-care highly active antiretroviral therapy (HAART). The objective of the trial is to assess the efficacy, safety and tolerability of PRO 140 as a long-acting, single-agent maintenance therapy for the chronic suppression of HIV. Patients enrolled in the trial will be shifted from daily HAART regimens to weekly PRO 140 subcutaneous injections for 48 weeks. This trial protocol is nearly a duplicate of the Phase 2b monotherapy trial, which is ongoing with an extension study that supports a group of patients who have maintained viral suppression for over two years and is continuing.

Additionally, the company has underway a Phase 2 trial to evaluate PRO 140 for Graft vs. Host Disease (GvHD) in a 100-day study involving 60 patients. GvHD is a life-threatening complication for cancer patients undergoing stem cell transplants. This trial will evaluate the safety and efficacy of PRO 140 for prophylaxis of acute GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic stem-cell transplantation.

CytoDyn operates under the guidance of a highly qualified management team and advisors with experience in a wide range of complementary skillsets, including business development, mechanical engineering, life sciences and biotech, manufacturing and clinical development, IP asset development, biologics, antibody drug conjugates, engineered tissue therapeutics, small molecule and radiopharmaceutical drugs and more. Additionally, CytoDyn has established relationships with world-class HIV experts who advise on the company’s trial designs.

For more information, visit www.CytoDyn.com

Rennova Health, Inc. (NASDAQ: RNVA, RNVAX), a vertically integrated public holding company serving the health care sector, focuses on offering comprehensive single-source solutions to health care providers ranging from diagnostic laboratory testing to technology solutions, revenue cycle management and financial and billing services. With a declared goal of creating efficient, innovative and empowering solutions, the company is dedicated to putting the needs of health care providers and their patients at the center of everything it does.

The company’s single-source solutions are designed to help health care providers increase operational efficiency and obtain added value, with the purpose of ultimately supporting better treatment outcomes, increasing patient care efficiency and optimizing revenue streams. Available individually or as a package, these industry-leading supportive software and diagnostics solutions and services work together to empower customers and help shape the next generation of health care.

The diagnostics testing solutions include highly complex clinical, toxicology and esoteric laboratory services, offered via Rennova Health’s subsidiary, Medytox Diagnostics, and its five labs located strategically across the country. These laboratories offer specialized services of urine drug testing for prescription medication, abuse drugs and pain medication, as well as toxicology, clinical chemistry, hematology, serology, immunology and esoteric testing services such as neurotransmitter tests. The testing and sampling process uses the company’s proprietary StableSpot™ methodology.

The company currently has an active customer base with 139 clients and possesses Medicaid licenses in a total of 28 states. Also part of its clinical lab operations segment, Rennova Health recently initiated the acquisition of various assets of a rural clinical access hospital that filed for Chapter 11 bankruptcy. The acquisition process is to be completed early next year, with the hospital and its laboratory likely back in operation in the third quarter of 2017. Another major acquisition the company plans is that of Genomics, Inc., a biomedical diagnostics company that offers personalized medicine via DNA-guided management. Genomics uses a patented combination of genes and a proprietary platform that correlates gene and physiological variability to come up with ideal medication for pain, diabetes, mental illness and heart disease.

Another essential component of Rennova’s comprehensive solutions offering is health care technology. The company’s integrated software solutions include both specialized applications and simplified technologies for electronic health records, an advanced laboratory information management system and a reporting application designed to help streamline diagnostic laboratory testing, as well as information solutions for precision oncology. The company launched an electronic health records service in the substance abuse sector in the last quarter of 2015 and currently has approximately 100 EHR clients across all verticals.

As for revenue cycle management services, Rennova’s in-house medical billing services solution, Medical Billing Choices, offers a customer-centered workflow designed to minimize errors, streamline customers’ billing cycles and maximize cash flow by expediting tasks such as insurance eligibility checks, claims submissions, and payment collecting. The company launched a specialized medical billing division for substance abuse facilities in the third quarter of the year and currently has approximately 20 facilities as customers.

Rennova also offers financial service solutions to health care providers, designed to help them maintain positive cash flows and overcome any income gaps cause by slow-to-pay customers. From special loans collaterized by accounts receivable to acquisitions of qualifying accounts receivable at a discounted rate, the company offers a wealth of financial solutions tailored to every customer.

For 2017 as well as long term, Rennova Health has plans to create and maintain a sustainable relationship with its customers, to grow revenue and provide added value to its shareholders by increasing and diversifying its diagnostics business, offering improved supportive software solutions and exploring new ways to improve provider and patient outcomes for various diagnostics, including cancer and diabetes. The company’s main target markets at the moment are pain management and drug and alcohol rehabilitation.

For more information, visit www.RennovaHealth.com

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future.

To view this week’s program, visit www.MoneyTV.net

In the interview, Greg Lambrecht, chief executive officer of Singlepoint, commented on the recent movement of the company’s stock, which has recorded above-average volume throughout much of the past two months. On November 4, in particular, Singlepoint’s volume climbed to 22.6 million. For comparison, the company’s average 30-day volume prior to this spike was roughly 4.35 million, according to OTC Markets. Singlepoint’s price per share recorded a similar spike in mid-November.

“We’ve had enormous response from funders, not only in New York but across the country, that are interested in investing in Singlepoint and also interested in helping us with some of our acquisitions,” Lambrecht stated in reference to the company’s recent volume. “We are in the process of looking at a couple of different funding deals and a couple of different acquisitions. It’s a very exciting time right now.”

One driver behind rising investor interest surrounding Singlepoint could be its ongoing forays into the legalized cannabis industry. In early November, the company announced plans to reawaken its SingleSeed subsidiary in order to gain access to the domestic cannabis market, which is projected to climb to $50 billion by 2026, according to data from financial services firm Cowen and Co. In line with these efforts, Singlepoint has recently turned its attention toward broadening its presence in the nation’s cannabis markets ahead of an expected resolution to the industry’s long-standing banking problem.

“One of the things we’re doing, we’re spending some money on really making our SingleSeed website live. That’s SingleSeed.com, and it is specifically set up for dispensaries,” Lambrecht told host Donald Baillargeon. “We’re turning that on to allow people to go in and sign one of our agreements and start to get our text message marketing, which is legal now, and sign up to get a terminal when it’s opened up.”

Lambrecht concluded the MoneyTV interview by taking a look at the current regulatory environment surrounding the cannabis industry. With President-elect Donald Trump having previously suggested plans to leave the regulation of recreational marijuana in the hands of individual states, Lambrecht predicts that it’s only a matter of time before a decision is made to give legal cannabis operations access to financial institutions and electronic payment solutions.

“A congressman from California has already written the Trump administration asking for a meeting,” Lambrecht concluded. “Basically, he’s saying, ‘Hey, California is opened up. These dispensaries need to have a bank account.’ So that, with Florida and Massachusetts, I think the pendulum has swung to where they’re going to let these dispensaries have bank accounts. When that happens, that’s going to be very exciting for Singlepoint.”

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

The increasing levels of solid waste generated in the U.S. each year is drawing attention from lawmakers, and strategies are being implemented on every level to address the issue. The U.S. Department of Agriculture (USDA) is taking steps (http://dtn.fm/tKM4H) to tap into the minds of state and local government entities, academic institutions, and private non-profit organizations by making available Solid Waste Management (SWM) and Technical Assistance and Training (TAT) grants to improve planning and management of solid waste sites in rural areas. In the business sector, National Waste Management Holdings (OTC: NWMH), a solid waste management company, has been steadily expanding its influence across the East Coast with an aggressive acquisition strategy that is bringing more and more facilities under its wing. The company’s comprehensive waste management approach includes an array of landfill disposal services, roll off containers for rental, and a line of recycled wood and garden mulch.

In a recent, exclusive audio interview (http://dtn.fm/7Yj2m) with NetworkNewsWire, a multifaceted financial news and publishing company, National Waste Management Holdings CEO Louis “Tiny” Paveglio and CFO Dali Kranzthor spoke toward a few of the company’s 2017 acquisition goals. A recent article cites a paper shredding facility in New York as being under consideration, and that acquisition would open NWMH to a sizable market in the region. As it stands, NWMH already services residential and commercial customers in Upstate New York, as well as in its home state of Florida.

An article (http://dtn.fm/8tRw2) from the Proceedings of the National Academy of Sciences of the United States of America found, upon examining the world’s megacities, that New York exceeds the rest in solid waste production, both in absolute and per capita terms. In addition, despite Tokyo being the largest megacity by population, New York surpasses it in terms of energy consumption of both transportation fuels and heating/industrial fuels. The article also states that New York consumes the energy of approximately two megacities; the equivalent of approximately one supertanker every 1.5 days. Interestingly, statistics in the 2014 Tables and Figures (http://dtn.fm/iWhx3) published by the EPA last month show that the Northeast more than doubles the rest of the nation in terms of municipal waste-to-energy capacity, with nearly 800 tons/day throughput per million people. Resource recovery facilities can turn solid waste into vital energy. One such facility, for example, is the Essex County Resource Recovery Facility that processed 2,800 tons of municipal solid waste per day in 2012 between its two generators, producing approximately 65 megawatts of energy.

While the Northeast led in terms of waste-to-energy capacity as well as estimated MRF throughput in 2014, it had, by far, the least number of landfills in the U.S., per the EPA report, potentially signifying a largely untapped market. SaveOnEnergy.com notes (http://dtn.fm/IebN2) that New York is the largest giver of trash to Ohio, accounting for nearly 32 percent of the state’s out-of-state total, with New Jersey coming in close behind. National Waste Management Holding’s initial acquisition strategies on the East Coast are part of the company’s larger objective of national expansion.

For more information, visit the company’s website at www.nationalwastemgmt.com

Let us hear your thoughts: National Waste Management Holdings, Inc. Message Board

For California-based PharmaCyte Biotech, Inc. (OTCQB: PMCB), a light at the end of the pipeline tunnel has become visible as one piece of good news follows another. The approval by the FDA to entertain a Pre-Investigational New Drug (Pre-IND) submission from the company sent PMCB stock soaring to triple its pre-approval value. The resulting market cap made PharmaCyte ‘primarily eligible’ to register securities for sale in an at-the-market (ATM) offering, which it now plans to do through Chardan Capital.

To make an ATM offering requires that the issuer be eligible, on a primary basis, to use a shelf registration statement on Form S-3. The Form S-3 filing initiates an equity distribution program under which, from time to time, ATM offerings can be made. Each ATM offering is a drawdown from the related shelf registration securities offering.

ATM offerings have a number of advantages. They typically cost less than traditional follow-on offerings, particularly since they are executed without high profile, expensive road shows. They also give an issuer the flexibility to determine the timing and size of any share sale, while allowing shares to ‘trickle’ into the market in a way that does not adversely affect the stock price.

PharmaCyte is now primarily eligible to use Form S-3 to offer securities, on its own behalf, for cash on an unlimited basis in ATM offerings, since the aggregate market value of its voting and non-voting common equity held by non-affiliates (i.e., the public float) is at least $75 million. The company intends to use funds received from the ATM offerings to advance the clinical trial process of its signature live-cell encapsulation technology, Cell-in-a-Box®.

PharmaCyte will be submitting a full Pre-IND package of information to the FDA that will set out essential elements of its planned Investigational New Drug (IND) application. After which, the FDA will review PharmaCyte’s manufacturing, preclinical pharmacology and toxicology, and clinical trial plans for the company’s therapy to treat locally advanced pancreatic cancer (LAPC). On successful completion of the review, PharmaCyte will be able to proceed with enrolment of the first clinical trial.

PharmaCyte’s clinical trial for LAPC is designed to meet a clear unmet medical need for those whose cancer no longer responds after 4-6 months of treatment with the combination of Abraxane® and gemcitabine. The trial will be open-label and multi-site in nature, with sites in the U.S. and Europe. Patients with LAPC will be randomized equally into two groups. One group will receive gemcitabine chemotherapy alone, and the other will receive PharmaCyte’s pancreatic cancer therapy. In addition to comparing the anticancer activity and safety of the two therapies, a major aspect of the trial will be to determine if, and how well, PharmaCyte’s therapy can shrink inoperable tumors so that they may become operable.

To work on its novel technology, Cell-in-a-Box®, PharmaCyte has assembled a respected team of oncologists that includes leading pancreatic cancer expert Dr. Daniel Von Hoff from Translational Drug Development (TD2), Dr. Manuel Hidalgo from Harvard Medical School, and Dr. Matthias Löhr from the Karolinska Institute in Stockholm, Sweden.

PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. The Cell-in-a-Box® therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or anti-carcinogenic form.

These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to the location of the implanted encapsulated cells.

When the ifosfamide comes in contact with the encapsulated cells, they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This targeted chemotherapy has proven effective and safe to use in past clinical trials and results in no side effects.

For more information, visit www.pharmacyte.com

An innovative potential treatment for hepatic encephalopathy created by Ocera Therapeutics, Inc. (NASDAQ: OCRX) is a unique product on an under-served market, and if clinical trials are successful, it could become a major source of success and profitability for the company, according to an Aegis Capital Corp. report (http://dtn.fm/J0h97) released on December 8. The report reiterates a ‘Buy’ rating for Ocera and recommends a higher stock price target of $8, compared to the $2.1 at the time of the analysis.

The Aegis report was released a day after Ocera announced completion of enrollment in its phase 2B trials for lead product candidate OCR-002 – an acute treatment for hepatic encephalopathy and hyperammonemia in patients with acute liver injury, acute liver failure and liver cirrhosis. The phase 2B study, called STOP-HE, will evaluate the safety, efficacy and tolerability of OCR-002 (Ornithine Phenylacetate) in hospitalized patients suffering from hepatic encephalopathy. The study enrolls a total of 230 subjects, which will be administered either OCR-002 or a placebo intravenously for five days. Based on their degree of liver impairment, patients will be given various doses of the drug, ranging from 10 to 20 grams over a 24-hour period.

Top-line data are due in the first quarter of 2017, which Aegis experts expect will be a share inflection point for the company. The study’s primary goal is to archive a meaningful clinical improvement in hepatic encephalopathy symptoms, so as to keep OCR-002 on track to potentially becoming a first-line, foundational therapy of choice for patients with this condition, on a market with significant unmet medical needs. Hepatic encephalopathy is a progressive complication of liver failure of cirrhosis which is marked by partial cognitive impairment including disorientation, confusion and impaired motor skills, while more severe forms can lead to coma and even the patient’s death.

According to the Agis report, there are currently only two hepatic encephalopathy products on the market, with others in development. Lactulose is a first-line therapy that has the largest market share at the moment, while Rifaximin is a second-line therapy. But Aegis analysts believe that OCR-002 has great potential and can take a significant market share, being unique in several respects: it has a unique mechanism of action as an ammonia scavenger, it is the only drug that can be administered intravenously and it has the potential to significantly shorten hospital stays.

If the phase 2B trial is successful, OCR-002 could reach approximately 170,000 patients that have hepatic encephalopathy and require hospitalization. Aegis analysts expect the therapy to achieve at least 22 percent market share and yield revenues of approximately $150 million. Ocera is also developing an oral formulation of the drug for chronic use, with the goal of preventing hepatic encephalopathy recurrences. The oral formulation was not included in the Aegis analysis, but it may indeed help provide an even larger share of the market.

As for potential risks for investors as identified in the report, these include typical manufacturing, commercialization, research and development, and regulatory risks that generally result from investing in pharmaceutical companies. The analysis also points out a series of specific risks of investing into Ocera, such as relying on the success of OCR-002, the company’s liquidity and high volatility.

For more information, visit the company’s website at www.ocerainc.com

U.S. home prices are going up steadily, having reached the highest peak in September after 2006’s real estate boom, a growth primarily driven by rising demand and a scarce inventory. The price hike came as a surprise to most real estate professionals, who expected a significant market slowdown in the last few months of 2016. While 2017 is likely to see more moderate growth, the market will continue to expand nonetheless, Realtor.com (http://dtn.fm/HdG6u) experts believe, as two of America’s largest generations – Millennials and baby boomers, are reaching a stage in their lives that typically motivates people to buy a home.

With this growing demand and a consistently smaller inventory, finding the right home will become more difficult than ever. GainClients, Inc. (OTC: GCLT), a leading provider of technology solutions for the real estate industry, aims at helping consumers look for and identify the right home for them via a comprehensive yet easy-to-use online search platform called GC HomeSearch (http://dtn.fm/AOI6o). The company’s declared goal is to offer simplified home search tools by providing buyers with a lot more information with a lot less, in an effort to make the home search process as easy and enjoyable as possible.

Through the online platform, buyers can get accurate and realistic knowledge of the homes they’re looking at, as well as the areas they’re located. This includes information such as home values, neighboring schools and services, demographic statistics, detailed property and neighborhood information, and more. Users can search as many properties as they want after registering for a free account. Search results can be sorted by city, state or zip code, and interesting properties can be saved for later viewing. Users can even find homes in their vicinity be entering the word ‘nearby’ in the search box.

The GC HomeSearch platform currently lists almost one million residential homes, which is encouraging given dwindling inventory numbers nationwide. According to Realtor.com statistics, the inventory of homes for sale in the top 100 metropolitan markets is going down at an average rate of 11 percent year after year, a trend that’s likely to continue next year as well.

The platform is the only GainClients service destined primarily to consumers, not real estate professionals, and was built with the intention of serving as a real estate community to all home buyers looking for their ideal property. For more in-depth information and backstage access to intelligent home buying and selling tools such as loan payment and rates calculators and closing cost estimates, users can link their GC HomeSearch account with the company’s flagship product, the GCard (http://dtn.fm/mQx7D) real estate networking system.

The GCard was designed with the primary purpose of helping real estate professionals connect and better communicate with their customers and other industry experts. This platform, accessible via web, mobile web, text message and smartphone app, gives real estate agents and lenders, as well as insurance agents, the means of providing consumers with the information they want when they want it. Professionals using this service are also able to network with each other, with the end goal of providing improved service to their clients.

For more information, visit the company’s website at www.gainclients.com

Let us hear your thoughts: GainClients, Inc. Message Board

How does a start-up venture capital-backed company grow its revenues to nearly a billion dollars in the global spine industry in less than two decades? By developing a competitive advantage in Speed of Innovation® and Absolute Responsiveness®, two concepts that have made NuVasive, Inc. (NASDAQ: NUVA) the number three company in the spine industry with over 90 products in its portfolio, including lumbar, thoracic, and cervical applications; neuromonitoring services; and biologics solutions.

The global spinal implants and surgical devices market ‘is expected to reach USD 17.27 Billion by 2021, growing at a CAGR of 5.3% from 2016 to 2021’, according to a press release from MarketsandMarkets (http://dtn.fm/uHV0W). Increasing longevity and the resulting larger elderly population means more spinal disorders, such as herniated discs, degenerative disc disease, spondylolisthesis, prolapsed intervertebral discs, and spinal stenosis. In addition, the development of minimally invasive surgical (MIS) procedures is leading to wider adoption of technologically advanced spinal implants.

MIS is NuVasive’s forte. The company is best known for developing the eXtreme Lateral Interbody Fusion® (XLIF) procedure, a minimally disruptive procedure that allows spine surgeons to have direct access to the intervertebral disc space (the “joint” of the spine) from the side of the body, as opposed to the front or back. The XLIF procedure is just one of the company’s many innovative procedures, which have redefined spine surgery and opened doors to treat pathologies not previously treated with minimal disruption.

NuVasive has also developed a revolutionary nerve avoidance monitoring system (NVJJB™ /M5®) designed to help ensure nerve and spinal cord safety – this unique and advanced technology may help reduce the incidence of injury to neural elements during spinal procedures by providing real-time feedback and notifying surgeons immediately of any neurological insult. Additionally, NuVasive offers a portfolio of biologics products to help in the bone healing process.

A recent report from Aegis Capital (http://dtn.fm/H1sQC) suggests that NuVasive’s rapid growth is far from over. The company has been steadily paring manufacturing inefficiencies. As a consequence, gross profit has hovered around 75 percent. Other operating margin improvements are expected from economies of scope as the marketing offering expands and economies of scale form an increasingly larger international footprint. Aegis sees “900bp of operating improvements to come, which will continue to drive value.”

In a fast growing industry (2–3% p.a.), NuVasive, focused on developing minimally disruptive surgical products and procedures for the spine, is a fast growing company (2-3x faster than the overall market). The drivers of growth are its ‘expanding platform of offerings, adapting a holistic approach with regards to its sales effort, and increased Integrated Global Alignment (iGA) integration which allows better planning for deformity and saves cost.’

Alignment is one of three important factors to be considered when spine surgery is being contemplated. In cases of spondylolisthesis, for example, the first concern is usually decompression of the nerves to ease any pain or discomfort the patient may be experiencing. In many instances, this means removing the disc or other offending piece from the spine. The resulting space is, typically, filled by bone graft or a synthetic substance in a procedure known as lumbar interbody fusion (LIF). At this point, alignment procedures to straighten the spine may be implemented.

NuVasive, which has a presence in over 30 countries and employs more than 1,600 people globally, had revenues of $811 million in 2015. A 17 percent increase to $953 million is expected this year. Aegis has initiated coverage with a ‘Buy’ rating and a price target of $72.00. The stock, trading on the NASDAQ under the symbol NUVA, is currently around $67.00.

For more information, visit www.nuvasive.com

Nano Dimension Ltd. (NASDAQ: NNDM) is the holding company for Nano Dimension Technology Ltd., a company in the business of researching, developing, and manufacturing three-dimensional (3D) printers for printed circuit boards (PCBs). The company also develops nano ink materials and other products for electronics. NNDM has the vision of revolutionizing the way electronics are made with 3D printing by using 3D printers for multilayer PCBs, along with advanced nanotechnology-based conductive and dielectric inks.

Since the beginning of last year, Nano Dimension has won the Europe 2015 Award for Best Development in 3D Printing Equipment, the Gartner ‘Cool Vendor’ in 3D Printing 2016, and the TÜV SÜD Innovation 2016 award. NNDM is equipped with an experienced managerial team with a long background in the technology and 3D printing spaces, and the company is well-positioned to capitalize on the PCB prototyping industry, which is currently worth approximately $70 billion.

With the launch of its new DragonFly 2020 3D Printer to select beta customers in the U.S., Israel, and Germany, during the third and fourth quarters of this year, Nano Dimension Ltd. is expected to make sales on a more commercial level as early as 2017. The printer, which comes with specialized 3D software as well as conductive and dielectric inks, has now received attention from over 2,500 entities currently on the information waitlist. In addition, more than 30 NDAs have been signed to enable the collaboration and evaluation of this equipment.

With its new printer, Nano Dimension Ltd. plans to provide its clients with more advanced solutions than ever before while tapping into additional markets. Through the DragonFly 2020 3D Printer, Nano Dimension expects to meet the needs of additional market segments by offering faster solutions that print larger objects from a broader materials portfolio with functional inks.

According to The Daily Quint (http://dtn.fm/j5xiP), Nano Dimension has been the topic of conversation for several research analysts firms, receiving a consensus ‘Buy’ rating from five investment analysts with a consensus average price target of $12.60 per share. At close of market on December 13, 2016, the company’s shares were sold at an individual price of $6.05. NNDM’s market capitalization currently stands at $46.96 million.

For more information, visit www.nano-di.com